[Asia Economy Reporter Lim Chun-han] A man in his 30s who was diagnosed with thrombocytopenic thrombosis syndrome (TTS) after receiving the AstraZeneca (AZ) COVID-19 vaccine has died.
The COVID-19 Vaccination Response Promotion Team announced via text message on the 16th, "The second confirmed case of thrombocytopenic thrombosis syndrome in the country passed away today at 2:10 PM."
The patient, a man in his early 30s, received the AstraZeneca 'leftover vaccine' on the 27th of last month. Nine days later, on the 5th of this month, he experienced severe headaches and vomiting and sought medical treatment, but his symptoms did not improve.
As his symptoms worsened and he experienced decreased consciousness unlike usual, he visited a higher-level hospital on the 8th of this month, 12 days after vaccination, where he was diagnosed with thrombocytopenic thrombosis syndrome.
This is the second confirmed case of thrombocytopenic thrombosis syndrome related to the AstraZeneca vaccine in South Korea, following the first case announced on the 31st of last month.
The Promotion Team stated, "Based on the epidemiological investigation results, we plan to review the progression from adverse reactions after vaccination to death with experts and improve any necessary areas." They added, "Procedures related to compensation, such as review by the damage investigation team and the damage compensation expert committee, will be expedited," and explained, "We will provide detailed information after epidemiological investigation and expert review."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
